Scarica l'app Stockscreener
1.09
1.80%
-0.02
Pre-mercato:
1.08
-0.01
-0.92%
Artelo Biosciences Inc Borsa (ARTL) Ultime notizie
Artelo Biosciences (ARTL) Reveals Positive Preclinical Data in N - GuruFocus
Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury - Yahoo Finance Singapore
Artelo presents research on FABP5 inhibitor ART26.12 - Investing.com UK
Artelo Biosciences Presents Evidence for a Common Lipid-Signaling Link Across Multiple Potential Indications for Its FABP5 Inhibitor Platform at ICRS 2026 - The Manila Times
Artelo Biosciences Reports Multi-Omics Findings Highlighting Linoleic Acid Link in ART26.12 FABP5 Inhibition - Quiver Quantitative
Artelo says its FABP5 inhibitor hits a key lipid pathway across disease models - Stock Titan
Artelo presents phase 1 data for FABP5 inhibitor ART26.12 - Investing.com UK
Artelo Biosciences Presents Clinical And Biomarker Data Supportive Of The Development Of ART26.12 And Follow-On FABP5 Inhibitors - marketscreener.com
Artelo Biosciences Presents Clinical and Biomarker Data Supportive of the Development of ART26.12 and Follow-On FABP5 Inhibitors at ICRS 2026 - The Manila Times
Artelo presents phase 1 data for FABP5 inhibitor ART26.12 By Investing.com - Investing.com Canada
Artelo Biosciences Reports Positive First-in-Human ART26.12 Safety and Pharmacokinetic Results, Advances AI-Enabled Biomarker Research - Quiver Quantitative
Artelo’s first-in-human FABP5 inhibitor shows tolerability, biomarker signals - Stock Titan
Artelo Biosciences Inc Actuals & Estimates (NASDAQ:ARTL) - TradingView
Artelo Biosciences Inc (ARTL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Why JOYY shares are trading higher by 12%; here are 20 stocks moving premarket - MSN
Artelo Biosciences (ARTL) asks shareholders to approve >20% issuance to Square Gate - Stock Titan
Artelo Biosciences Inc (ARTL) Institutional Confidence - TradingKey
ARTELO BIOSCIENCES INC (ARTL) Stock Chart - ChartMill
Artelo Biosciences Inc (ARTL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Artelo Biosciences Inc (ARTL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Artelo Biosciences Inc (ARTL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Artelo Biosciences Inc (ARTL) Valuation: PE, PB & Fair Value Analysis - TradingKey
Artelo Biosciences Expands Horizons with Strategic Trials - timothysykes.com
Artelo Biosciences Targets Glaucoma Market with Strategic Drug Development - timothysykes.com
ARTL Q4 2025 Earnings: EPS Surprise of 97.5% Beats EstimatesGuidance Upgrade Report - newsline.com
Artelo Biosciences Surges with Groundbreaking Glaucoma Study Announcement - timothysykes.com
Artelo Biosciences (ARTL) Rebounds 3%: Key Support Holds Amid Biotech Sector VolatilityValue Area High - newsline.com
Artelo Biosciences discloses positive ART26.12 metabolite profile - grafa.com
Artelo Biosciences reports favorable metabolism... | Pluang – Crypto, Stocks, Gold & Funds - Pluang
Artelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Associated with Clinical Development Success - The Manila Times
Artelo Biosciences Company Profile & Introduction - Moomoo
Artelo Biosciences, Inc. - MLQ.ai
[ARS] ARTELO BIOSCIENCES, INC. SEC Filing - Stock Titan
Artelo Biosciences (NASDAQ: ARTL) proxy seeks large boost in authorized shares - Stock Titan
ARTL Stock Price, Quote & Chart | ARTELO BIOSCIENCES INC (NASDAQ:ARTL) - ChartMill
Artelo Biosciences Q4 2025 Earnings: Massive EPS Beat Despite Zero Revenue, Stock DeclinesEstimate Accuracy - newsline.com
Artelo Biosciences Launches Flexible At-The-Market Offering - The Globe and Mail
Artelo Biosciences, Inc. Announces At The Market Offering Agreement With H.C. Wainwright & Co - Minichart
Artelo Biosciences (ARTL) Gains 7.35%: Biotech Stock Tests Resistance Near $1.53Combination Correction - newsline.com
Artelo Biosciences stock tumbles on $6.5M share offering - Investing.com
Artelo Biosciences Launches $6.53 Million ATM Equity Program With H.C. Wainwright - TradingView
[8-K] ARTELO BIOSCIENCES, INC. Reports Material Event - Stock Titan
Dow Jumps Over 300 Points; Dick's Sporting Shares Fall After Q1 Results - Benzinga
Artelo Biosciences stock tumbles on $6.5M share offering By Investing.com - Investing.com Nigeria
Artelo Biosciences to offer up to $6.53 million in common stock via H.C. Wainwright - marketscreener.com
Artelo Biosciences To Offer Up To $6.53 Million In Common Stock Via H.C. Wainwright - TradingView
Artelo Biosciences (ARTL) asks shareholders to approve 500M-share authorization - Stock Titan
Artelo Biosciences (ARTL) launches $6.53M at-the-market program with HCW - Stock Titan
Tuesday's session: top gainers and losers - ChartMill
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
ARTL Stock In Focus As Artelo Biosciences Taps AI For Drug Pipeline - StocksToTrade
ARTLArtelo Biosciences Inc Stock Price and Quote - Finviz
Artelo Biosciences ARTL Jumps On AI Drug Discovery Pact - timothysykes.com
Which stocks are moving before the opening bell on Tuesday? - ChartMill
Why JOYY Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket - Benzinga
Wondering what's happening in today's after-hours session? - ChartMill
Artelo Biosciences (ARTL) Slides 10.5% as Shares Test Key Support LevelsBuffered ETF - newsline.com
Why did ARTL stock skyrocket over 141% pre-market today? - MSN
Trending Stocks Today | Artelo Biosciences Soars 69.19% Post-Market - Moomoo
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Get insights into the top gainers and losers of Friday's after-hours session. - ChartMill
[EFFECT] ARTELO BIOSCIENCES, INC. SEC Filing - Stock Titan
0.05%
0.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):